Cyberonics Disappoints - Analyst Blog
June 03 2011 - 6:30AM
Zacks
Cyberonics (CYBX)
reported fourth quarter 2011 EPS of 26 cents, which missed the
Zacks Consensus Estimate of 29 cents and were far behind the
year-ago quarter’s adjusted earnings (excluding the impact of gain
on early extinguishment of debt) of 40 cents. Despite higher sales
and a roughly 50.6% reduction in interest expense, the decline in
the bottom line was attributable to significant increase in income
tax expense ($5.5 million in the reported quarter compared with the
year-ago quarter’s $.03 million). Fiscal 2011 earnings were $1.63
per share, beating the Zacks Consensus Estimate of $1.04 but
trailing the previous year’s EPS of $ 2.62.
During the quarter, Cyberonics
reported revenues of $51.1 million, up 7.1% year over year but
marginally missing the Zacks Consensus Estimate of $52 million. The
growth was based on 13% higher sales in the U.S ($44 million),
partly offset by lower international revenues ($7.01 million), but
was in line with the past two quarters. For the full year, revenues
increased 14% to $190.5 million compared to the Zacks Consensus
Estimate of $191 million.
In spite of increased investment in
the European market, the international sales suffered primarily due
to the negative impact of the Japan crisis and related uncertainty
in that market. However, the company expects international growth
to resume in fiscal 2012.
Cyberonics’ strong sales
performance in the U.S was on the back of robust growth in the
company’s epilepsy business driven by higher volume and increased
average selling prices. Several physician education programs,
recently published data and effective sales force execution
resulted in a successful quarter. Moreover, the company’s initial
demand for the AspireHC generator, in limited commercial release,
was also encouraging.
Gross margin for the quarter
declined 60 basis points (bps) to 87.9% due to a 12.7% rise in cost
of revenue. A 2.3% increase in selling, general and administrative
expenses coupled with a 21.3% rise in research and development
expenses led to a 6.3% rise in operating expenses. As a result,
despite a 6.3% rise in income from operations to $13.0 million,
operating margin contracted 14 bps year over year to 25.4%.
Cyberonics exited the quarter with
$89.3 million in cash and cash equivalents, up 50.8% from $59.2
million reported in the previous quarter.
Guidance
Cyberonics provided its outlook for
fiscal 2012. The company expects revenues and income from
operations in the range of $212 – $215 million and $54 – $57
million, respectively (the Zacks Consensus Revenue Estimate for
fiscal 2012 was $216 million). In addition, the company also
expects the effective tax rate to be approximately 40% in fiscal
2012 while cash payments for income taxes will not exceed 3% of
income before tax in fiscal 2012 and 2013.
Recommendation
Although Cyberonics witnessed an
expansion in the top line attributable to the company’s strong
position in the US epilepsy market we remain concerned about
several headwinds faced by the company while establishing its
foothold in international arena. We are concerned about the
competitive pressure in the neuromodulation market from players
such as Medtronic (MDT) and St.
Jude (STJ). Currently, we have a long-term Neutral
recommendation on Cyberonics.
CYBERONICS INC (CYBX): Free Stock Analysis Report
MEDTRONIC (MDT): Free Stock Analysis Report
ST JUDE MEDICAL (STJ): Free Stock Analysis Report
Zacks Investment Research
SJM (NYSE:STJ)
Historical Stock Chart
From May 2024 to Jun 2024
SJM (NYSE:STJ)
Historical Stock Chart
From Jun 2023 to Jun 2024